Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 7/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15188827 | 1.00 | RAPGEF3 (1.00) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL15941194 | 1.00 | RAPGEF3 (1.00) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL15175346 | 0.89 | RAPGEF3 (1.00) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL15175342 | 0.89 | RAPGEF3 (1.00) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL15176034 | 0.88 | RAPGEF3 (0.79) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL15176035 | 0.88 | RAPGEF3 (0.79) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL15176283 | 0.88 | RAPGEF3 (0.82) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL15176289 | 0.88 | RAPGEF3 (0.82) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL15175066 | 0.88 | RAPGEF3 (0.78) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL15175065 | 0.88 | RAPGEF3 (0.78) | RAPGEF3ALBRAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| CN-118924760-A | Application of CGP60474 in preparation of medicines for treating bladder cancer | 兰州大学 | 2024-11-12 | — | — | CN | claimed |
| CN-117942337-B | Application of ESI-09 in preparation of medicines for treating bladder cancer | 兰州大学 | 2024-07-09 | — | — | CN | claimed |
| CN-117942337-A | Application of ESI-09 in preparation of medicines for treating bladder cancer | 兰州大学 | 2024-04-30 | — | — | CN | claimed |
| CN-114869883-B | Application of ESI-09 in prevention and treatment of SVCV infection | 中国科学院水生生物研究所 | 2023-06-20 | — | — | CN | claimed |
| CN-115040511-B | Application of ESI-09 in preventing and treating GCRV infection | 中国科学院水生生物研究所 | 2023-05-23 | — | — | CN | claimed |
| CN-115040511-A | Application of ESI-09 in prevention and treatment of GCRV infection | 中国科学院水生生物研究所 | 2022-09-13 | — | — | CN | claimed |
| CN-114869883-A | Application of ESI-09 in prevention and treatment of SVCV (SVCV) infection | 中国科学院水生生物研究所 | 2022-08-09 | — | — | CN | claimed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122070916-A | Application of arteannuin with double functions in promoting liver cell maturation and relieving liver lipid metabolism dysfunction | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 2026-05-22 | — | — | CN | disclosed |
| EP-4729940-A2 | LARGE SCALE ORGANOID ANALYSIS | Tempus AI, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-08 | — | — | US | disclosed |
| US-20260011445-A1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-11415571-B2 | Large scale organoid analysis | TEMPUS LABS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| WO-2021188728-A9 | SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-11 | — | — | WO | disclosed |
| CN-114869883-A | Application of ESI-09 in prevention and treatment of SVCV (SVCV) infection | 中国科学院水生生物研究所 | 2022-08-09 | — | — | CN | disclosed |
| CN-114869883-A | Application of ESI-09 in prevention and treatment of SVCV (SVCV) infection | 中国科学院水生生物研究所 | 2022-08-09 | — | — | CN | disclosed |
| CN-114869883-A | Application of ESI-09 in prevention and treatment of SVCV (SVCV) infection | 中国科学院水生生物研究所 | 2022-08-09 | — | — | CN | disclosed |
| US-20220160723-A1 | PHARMACOLOGICAL MITIGATION OF LATE-STAGE TOXEMIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260011445-A1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | BRCA1, PARP2, PARP4 | RAPGEF3 1695/4885ALB 4840/4885RAPGEF4 1525/4885 |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | RAPGEF3 169/4885ALB 4867/4885RAPGEF4 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.